Effect of olive extract on heart and blood vessel function
Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function of Patients With Stable Coronary Artery Disease
NA · University of Athens · NCT04520126
This study is testing whether olive extract can improve heart and blood vessel function in people with coronary artery disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Athens (other) |
| Locations | 1 site (Athens, Attica) |
| Trial ID | NCT04520126 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of olive extracts, specifically hydroxytyrosol and a combination of Oleuropein, Hydroxytyrosol, and Oleocanthal, on endothelial, cardiac, and vascular function in patients with coronary artery disease. A total of 30 patients with stable coronary artery disease will be randomly assigned to receive either the olive extract capsules or a placebo for one month, followed by a switch to the alternate treatment for another month. The goal is to assess the potential benefits of these extracts on heart health and vascular function.
Who should consider this trial
Good fit: Ideal candidates for this study are patients under 70 years old with stable coronary artery disease and specific lipid profile abnormalities.
Not a fit: Patients over 70 years old, those with diabetes, hypertension, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural treatment option to improve heart and vascular health in patients with coronary artery disease.
How similar studies have performed: While the specific combination of olive extracts is novel, previous studies have indicated potential benefits of olive oil and its components on cardiovascular health.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \<70 years 2. Stable coronary heart disease 3. Patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), 2 months must have passed since the incident 4. High LDL levels, low HDL, high triglycerides Exclusion Criteria: 1. Age\> 70 years 2. Patient with diabetes 3. Patient with hypertension 4. Patient with liver disease 5. Patient with thyroid disease 6. Patient with active malignancy 7. Patient with a disease that affects inflammatory markers (rheumatic diseases, etc.) 8. Patient with chronic renal failure (creatinine\> 2 mg / dl) 9. Patient treated chronically with corticosteroids 10. Patient who has joined a weight loss program or any dietary intervention or intensive exercise programme within the previous 2 months or consumes multivitamin preparations with antioxidant properties.
Where this trial is running
Athens, Attica
- "Attikon" University General Hospital — Athens, Attica, Greece (RECRUITING)
Study contacts
- Principal investigator: Ignatios Ikonomidis — 2nd Cardiology Department, National and Kapodistrian University of Athens, Attikon General Hospital
- Study coordinator: Ignatios Ikonomidis
- Email: ignoik@gmail.com
- Phone: +302105832187
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Artery Disease, olive oil, myocardial deformation, glycocalyx